Placebo News and Research

RSS

Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma

An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage IIb and IIc melanoma, according to the results of an international, randomized phase III clinical trial led by UPMC Hillman Cancer Center.

20 Sep 2021

A new synthetic multiantigen MVA vaccine COH04S1 effective against SARS-CoV-2

A new study utilized MVA to develop vaccine candidates that were subsequently evaluated in animal models of congenital cytomegalovirus disease.

19 Sep 2021

mAb treatment can rapidly select for SARS-CoV-2 resistance, suggests study

A study evaluates the efficacy of a mAb to prevent disease progression in non-hospitalized persons with symptomatic SARS-CoV-2 infection.

17 Sep 2021

Researchers disprove natural antioxidant urate for slowing the progression of Parkinson’s disease

The hypothesis that raising the brain levels of the natural antioxidant urate could slow the progression of Parkinson's disease (PD) has been disproven by researchers at Massachusetts General Hospital.

14 Sep 2021

Researchers explore whether cocoa supplementation can reduce aging

Whether consuming cocoa, known to be packed with powerful antioxidants that protect our cells from damage, helps us age better, is a question scientists want to definitively answer.

14 Sep 2021

A review of mesenchymal stem cell therapy for severe COVID-19

Researchers find that MSC treatment is highly tolerated and effective in reducing lung damage in COVID-19 patients and improving their chances of recovery.

13 Sep 2021

Virus-like nanoparticle vaccine effective against SARS-CoV-2 in animal model

A COVID-19 vaccine, created from a virus-like nanoparticle that displays SARS-CoV-2 spike protein RBDs, effectively protects animal model from infection.

10 Sep 2021

Post-exposure prophylaxis with monoclonal antibodies may reduce health system burden in the US

In a study conducted at the University of Washington, USA, the researchers assert that post-exposure prophylaxis with monoclonal antibodies could improve the clinical outcomes and health system costs regarding coronavirus disease (COVID-19). The study is currently available on the medRxiv* preprint server.

6 Sep 2021

Rheumatoid arthritis drug plus standard of care may reduce COVID-19 mortality for hospitalized patients

Hospitalized patients with COVID-19 who received the rheumatoid arthritis drug baricitinib, in combination with the standard of care including corticosteroids, died less often than those receiving only the standard of care, according to a study released this week in The Lancet Respiratory Medicine.

1 Sep 2021

Investigational vaccine does not provide sufficient protection against HIV infection

An investigational HIV vaccine tested in the "Imbokodo" clinical trial conducted in sub-Saharan Africa posed no safety concerns but did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. The Phase 2b proof-of-concept study, which began in November 2017, enrolled 2,637 women ages 18 to 35 years from five countries.

31 Aug 2021

J&J COVID-19 booster shot produces robust antibody response

The study showed neutralizing antibody responses produced by the Johnson & Johnson–Janssen vaccine was robust and stable eight months after immunization.

31 Aug 2021

FDA grants seven years of marketing exclusivity for Octapharma’s Octagam 10%

Octapharma USA today announced the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded seven years of marketing exclusivity for Octagam® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis (DM).

31 Aug 2021

AI approach helps identify heart failure patients who will benefit from beta-blocker therapy

Researchers at the University of Birmingham have developed a new way to identify patients with heart failure who will benefit from treatment with beta-blockers.

31 Aug 2021

New evidence provides strong support for the halt on prescribing hydroxychloroquine for COVID-19

In 2021, in the United States alone, there have been more than 560,000 prescriptions of hydroxychloroquine for the prevention, post-exposure and treatment of COVID-19.

31 Aug 2021

Scientists identify potential biomarkers to predict COVID-19 outcomes

A team of scientists from the United States has recently examined the trajectory of early immune biomarkers in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. They have identified specific plasma proteins that can accurately predict the clinical and virological outcomes in SARS-CoV-2 infected patients. The study is currently available on the medRxiv* preprint server.

31 Aug 2021

Influenza vaccination should become a part of standard hospital care after myocardial infarction

Influenza vaccination reduces the risk of all-cause death, myocardial infarction, or stent thrombosis at 12 months in hospitalized patients with myocardial infarction or high-risk coronary disease, according to late breaking research presented in a Hot Line session today at ESC Congress 2021.

30 Aug 2021

$Study identifies drug with a positive effect on heart failure patients with preserved ejection fraction$

Study identifies drug with a positive effect on heart failure patients with preserved ejection fraction

Until now, patients with heart failure with preserved ejection fraction – the most common type of heart failure in the elderly – have had no access to evidenced-based treatments. For the first time, a large clinical trial led by Prof. Dr. Stefan Anker from Charité – Universitätsmedizin Berlin has identified a drug which has a distinctly positive effect on prognosis. In patients affected by this type of heart failure, the drug – empagliflozin – reduces the risk of hospitalization or cardiovascular death by 21 percent. The results of this research have been published in the New England Journal of Medicine.

28 Aug 2021

$Analysis shows benefits of empagliflozin in heart failure patients with reduced and preserved ejection fraction$

Analysis shows benefits of empagliflozin in heart failure patients with reduced and preserved ejection fraction

A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a Hot Line session today at ESC Congress 2021 and published in the New England Journal of Medicine.

27 Aug 2021

ACTG announces positive data for monoclonal antibody combination therapy from the ACTIV-2 study

The AIDS Clinical Trials Group, the largest global HIV research network, which has expanded its focus to include evaluating outpatient treatment for COVID-19, today announced positive data for the monoclonal antibody combination therapy BRII-196/BRII-198 from the ACTIV-2 study of Outpatient Monoclonal Antibodies and Other Therapies.

27 Aug 2021

Researchers receive $14 million grant to study the effectiveness of hydrocephalus treatment

Patients diagnosed with idiopathic normal pressure hydrocephalus (iNPH), a type of brain swelling most commonly seen in older adults — and for which the underlying cause is unknown — are typically treated by surgically installing a shunt (drain) to remove the excess fluid associated with the condition.

26 Aug 2021

Placebo News and Research

Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma

A new synthetic multiantigen MVA vaccine COH04S1 effective against SARS-CoV-2

mAb treatment can rapidly select for SARS-CoV-2 resistance, suggests study

Researchers disprove natural antioxidant urate for slowing the progression of Parkinson’s disease

Researchers explore whether cocoa supplementation can reduce aging

A review of mesenchymal stem cell therapy for severe COVID-19

Virus-like nanoparticle vaccine effective against SARS-CoV-2 in animal model

Post-exposure prophylaxis with monoclonal antibodies may reduce health system burden in the US

Rheumatoid arthritis drug plus standard of care may reduce COVID-19 mortality for hospitalized patients

Investigational vaccine does not provide sufficient protection against HIV infection

J&J COVID-19 booster shot produces robust antibody response

FDA grants seven years of marketing exclusivity for Octapharma’s Octagam 10%

AI approach helps identify heart failure patients who will benefit from beta-blocker therapy

New evidence provides strong support for the halt on prescribing hydroxychloroquine for COVID-19

Scientists identify potential biomarkers to predict COVID-19 outcomes

Influenza vaccination should become a part of standard hospital care after myocardial infarction

Study identifies drug with a positive effect on heart failure patients with preserved ejection fraction

Analysis shows benefits of empagliflozin in heart failure patients with reduced and preserved ejection fraction

ACTG announces positive data for monoclonal antibody combination therapy from the ACTIV-2 study

Researchers receive $14 million grant to study the effectiveness of hydrocephalus treatment

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News